Wednesday, February 19, 2020

Antidepressants & Anxiolytics with Low Risk of Sexual Dysfunction

Antihistamines
  • Atarax
  • Mirtazapine (also a Tetracyclic drug)
    • Mirtazapine can be stacked on top of an SSRI to reduce sexual dysfunction. The results are typically seen later after 4–8 weeks.
  • Chlorphenamine might be able to reduce SSRI sexual dysfunction.


Azapirones
  • Buspirone
    • Buspirone can be stacked on top of an SSRI to reduce sexual dysfunction.
      Try taking 5-10 mg, 3-4 times daily, in addition to your SSRI.
  • Tandospirone (probably  low risk of sexual side effects - do your research)


Atypical antidepressants
  • Bupropion A.K.A Wellbutrin
    • Wellbutrin can be stacked on top of an SSRI to reduce sexual dysfunction.
  • Agomelatine
    • Agolematine might be able to reduce SSRI sexual dysfunction.


Serotonin Antagonists 
  • Vilazodone
  • Vortioxetine


SNRIs
  • Duloxetine
    • (33.3% of duloxetine patients experienced sexual side effects compared to 43.6% of those receiving escitalopram and 25% of those receiving placebo).

MAOIs
  • Selegiline (transdermal patch)


GABAergics 
  • As I understand it, GABAergics do not cause sexual dysfunction.
    Click here for a list of all GABAergics.

Reducing Sexual Side Effects of SSRI Medication

Cabergoline
there is some evidence that it counteracts reduced libido and anorgasmia. It also has been suggested that it has a possible recreational use in reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession, and at least two scientific studies support those speculations.

Nortriptyline 
Anecdotal evidence shows that Nortriptyline might be able to counter the sexual side effects of SSRI.

Ginkgo Biloba (240 mg per day)
"in an open trial of various formulations, ginkgo was found to be effective in 84% of patients with sexual dysfunction induced by antidepressants".

Cannabis
Cannabis is a strong aphrodisiac. If you search, you'll find plenty of self-reports of its aphrodisiac effects.

Sildenafil, Tadalafil, Vardenafil (Viagra, Cialis, Levitra)
Can be used for males who only suffer from erectile dysfunction. These drugs do not affect libido or pleasure, only erection.

Supplements that may increase sexual function

  • Yohimbine
  • Panax Ginseng
  • Maca capsules
  • L-Arginine
  • Zinc
  • Selenium
  • L-Citrulline
  • L-Ornitine
  • Rhodiola Rosea
  • Trigonella Foenum Graceum
  • Niacine
  • Terminalia Chebula Extract
  • Mucuna Pruriens
  • Urtica Dioica
  • Muira Puama extract
  • Silybum Marianum


What is the cause of sexual dysfunction with antidepressants? 
It is thought that 5HT2c receptor agonism, which is increased serotonin transmission by blocking SERT, is the cause of sexual dysfunction.

5HT2c antagonists are likely to block the effect of SSRI sexual dysfunction.
Prozac actually blocks 5HT2c, but not strongly.

Tuesday, January 7, 2020

ALL Drugs and Supplements for Anxiety/Depression

I compiled these lists because psychologists/psychiatrists rarely explain which medications are available and may even withhold information. These lists are non-exhaustive but contain most common substances. If any of these substances are legally available in your area, try them out one at a time until you find what substance and dosage works for your brain/body. 

These drugs are either officially indicated, OR off-label.


DO YOUR RESEARCH. Most doctors don't.


Also, see: Drugs/Psychedelics for Anxiety/Depression

Synthetic drugs for anxiety/depression

  • GABA reuptake inhibitors
    • Tiagabine (anticonvulsant, used off-label for anxiety and panic disorder)
  • Gabaergics
    Gabaergics are mainly used for anxiety or insomnia. Some can also give euphoric effects. As I understand it, GABAergics do not cause sexual dysfunction.
    • Abecarnil 
    • alprazolam
    • Baclofen (indicated for muscle spasms, but Euphoria is listed as a common side-effect in the BNF 75, and it can also have anxiolytic effects.)
    • Chlordiazepoxide
    • Clobazam 
    • clonazepam
    • clorazepate
    • diazepam
    • Divaplon
    • Eszopiclone (Lunesta)
    • Etifoxine (binds to GABA-A and purportedly to the TSPO)
    • Fasiplon 
    • gabapentin
    • gabapentin enacarbil
    • gabapentin prodrug
    • Lorazepam
    • midazolam
    • mirogabalin
    • Necopidem
    • Nordazepam
    • Nitrous Oxide
      • (In behavioural tests of anxiety, a low dose of N2O is an effective anxiolytic, and this anti-anxiety effect is associated with enhanced activity of GABAa receptors, as it is partially reversed by benzodiazepine receptor antagonists. )
    • oxazepam
    • Pagoclone
    • Panadiplon 
    • Pazinaclone 
    • phenibut
    • piracetam
    • pregabalin
    • Saripidem
    • Suproclone
    • Suriclone (Suril)
    • Taniplon 
    • Tofisopam (does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing or amnestic properties.)
    • Zaleplon
    • ZK-93423
    • Zolpidem
    • Zopiclone
  • Gabaergics (in development/research)
    • CGS-20625 
    • CGS-9896
    • CL-218,872 
    • DS-1  
    • ELB-139 (LS-191,811)
    • GBLD-345 
    • L-838,417 
    • Lorediplon 
    • NS-2664 (LS-193,048) 
    • NS-2710 (LS-193,970) 
    • RWJ-51204 
    • SB-205384 
    • SL651498
    • SX-3228
    • TP-003 
    • TP-13 
    • TPA-023 (MK-0777)  
    • Y-23684
  • Stimulants (possible use for anxiety/depression)
    • methylphenidate
      • (there are several case reports of methylphenidate inducing serotonin syndrome with concomitant administration of antidepressants.)
    • dextroamphetamine
  • Antihistamines and Neuroleptics
    • Atarax (low risk of sexual side effects)
    • Chlorphenamine A.K.A Chlorpheniramine (low risk of sexual side effects)
      • Although not generally approved as an antidepressant or anti-anxiety medication, chlorphenamine appears to have these properties as well.
    • Mirtazapine (also a Tetracyclic drug(low risk of sexual side effects)
    • Promethazine (sedative, but might work for anxiety)
    • Alimemazine (sedative. in Russia, it is marketed for the treatment of anxiety disorders)
    • Levomepromazine (sedative and antipsychotic, but might work for anxiety)
  • Tricyclic Antidepressants
    • Protriptyline
    • Noxiptiline (brand names Agedal, Elronon, Nogedal)
    • Nortriptyline 
    • Amitriptyline
  • Serotonin Agonists / Azapirones
    • Buspirone (low risk of sexual side effects)
    • Tandospirone (probably low risk of sexual side effects - do your research)
  • Tetracyclic Antidepressants
    • Trazodone
    • Maprotiline
  • SSRIs
    • Citalopram
    • Escitalopram
    • Fluoxetine
    • Fluvoxamine
    • Fluvoxamine controlled release
    • Paroxetine
    • Sertraline
  • Atypical antidepressants
    • Tianeptine
    • mianserin
    • bupropion (low risk of sexual side effects)
    • trazodone
    • nefazodone
    • opipramol
    • agomelatine (low risk of sexual side effects)
  • Serotonin Antagonists 
    • Pizotifen (used off-label for: depression, anxiety, social phobia)
       (doesn't seem to cause sexual side effects)
  • Serotonin Modulators
    • Vilazodone (low risk of sexual side effects)
    • Vortioxetine (low risk of sexual side effects)
  • SNRIs
    • Venlafaxine
    • Desvenlafaxine
    • Milnacipran (only available in Austria and Israel)
    • Duloxetine
      • (33.3% of duloxetine patients experienced sexual side effects compared to 43.6% of those receiving escitalopram and 25% of those receiving placebo).
  • Opiates / Opioids (possible use for anxiety/depression)
    • Buprenorphine, sold under the brand name Subutex, among others
  • MAOIs
    • Nardil
    • Parnate
    • Selegiline (transdermal patch) (low risk of sexual side effects)
  • Synthetic Cannabinoids
    • Sativex
    • Marinol
    • Epidiolex

Antipsychotics (possible use for anxiety/depression)
  • Prochlorperazine (Efficacy established in patients with generalized anxiety disorder -- McEvoy GK, ed. Prochlorperazine. Bethesda, MD: American Society of Health-System Pharmacists; 2005:2342-3)


substituted benzamides (possible use for anxiety/depression)
  • Levosulpiride  (used for psychosis, schizophrenia, anxiety, dysthymia)


atypical antipsychotics (possible use for anxiety/depression)
  • Sulpiride ( used in low dosage to treat anxiety and mild depression.)
  • Amisulpride (schizophrenia,  dysthymia)


Other drugs (possible use for anxiety/depression)


Unknown effect, might be of interest for anxiety/depression




Herbs/supplements for anxiety/depression:

  • St. John's Wort
    • ("For patients with mild-to-moderate depression, St John's wort has comparable efficacy and safety when compared to SSRIs.")
  • 5HTP (griffonia simplicifolia)
  • Cannabis (high-CBD edibles)
  • CBD oil
  • chamomile capsules
  • GABA capsules (e.g NOW Foods GABA)
  • glycine
  • Holy basil extract
  • hops capsules
  • inositol
  • Lavender capsules
  • lion's mane mushroom
  • Magnesium glycinate
  • Magnesium oil + iodine = zen mode 
  • Magnesium taurate
  • Magnsieum citrate
  • Lemonbalm/melissa capsules
  • niacinamide
  • Omega3
    • ("Emmons recommends a dose of 2,000 to 4,000 mg or more when taken for mood problems")
  • SAMe 200mg (S-Adenosyl-Methionine) 
  • Suntheanine / L-Theanine
  • taurine
    • (take 600mg or more in a single serving)
  • valerian extract capsules
  • vitamin B6
  • Vitamin D3 5000 IU
    • (good for Seasonal Depression, adults should take 5,000 IU per day. )
  • Vitamine C and E works against Oxidative stress



Probiotics for anxiety / depression:

When they give probiotics to mice suffering from autism symptoms, the autism symptoms either go completely away or are strongly ameliorated.

  • Lactobacillus helveticus Rosell-52 ME
  • Bifidobacterium longum Rosell-175 ME
  •  Lactobacillus  acidophilus La14
  • Lactobacillus  Rhamnosus R0011
  • Lactobacillus helveticus R0052
  •  Lactobacillus  casei Lc11
  •   Lactobacillus  paracasei lpc37
  •    Lactobacillus  plantarum lp115
  •   Lactobacillus  salivarius ls33
  •   Bifidobacterium  lactis BI04
  •  Bifidobacterium  breve br03
  •    Bifidobacterium  longum bb536





Misc info (possible use for anxiety/depression)
Magnesium and vitamin K2 complement each other, as magnesium helps lower blood pressure, which is an important component of heart disease. So, all in all, anytime you're taking any of the following: magnesium, calcium, vitamin D3, or vitamin K2, you need to take all the others into consideration as well, since these all work synergistically with one another.

Magnesium is required for the biological activation of Vitamin D.
Calcium and magnesium are necessary for muscle function and nervous system health. If you don't have enough, you can have problems with clenching, tension, and other muscle problems.

  • "by using vitamin B3 or niacin or niacinamide, which has effect upon gaba receptors but, after ive started especially With magnesium, manganese and lithium, ive needed much less diazepam when i first use it"

  • Kent Holtorf MD says on twitter: "T3 is the best anti-depressant".

Please inform me if you know about a substance not present in the blog post above.

Wednesday, August 14, 2019

You don't need 8 glasses of water a day

MYTH: You should drink at least eight glasses of water a day. 

FACT: "There is no medical evidence to suggest that you need that much water," said Dr. Rachel Vreeman, a pediatrics research fellow at the university and co-author of the journal article. Vreeman thinks this myth can be traced back to a 1945 recommendation from the Nutrition Council that a person consume the equivalent of 8 glasses (64 ounces) of fluid a day. Over the years, "fluid" turned to water. But fruits and vegetables, plus coffee and other liquids, count.


"7 Medical Myths Even Doctors Believe", LiveScience <http://www.livescience.com/health/071220-medical-myths.html>. 20 December 2007

Wednesday, December 21, 2016

ALL Drugs, Herbs, and Supplements for Anxiety / Depression

I compiled these lists because psychologists/psychiatrists rarely explain which medications are available and may even withhold information. These lists are non-exhaustive but contain most common substances. If any of these substances are legally available in your area, try them out one at a time until you find what substance and dosage works for your brain/body. 

These drugs are either officially indicated, OR off-label.


DO YOUR RESEARCH. Most doctors don't.


Also, see: Drugs/Psychedelics for Anxiety/Depression

Synthetic drugs for anxiety/depression

  • Gabaergics
    Gabaergics are mainly used for anxiety or insomnia. Some can also give euphoric effects. As I understand it, GABAergics do not cause sexual dysfunction.
    • Abecarnil 
    • List of benzos on Wikipedia: https://en.wikipedia.org/wiki/Template:Benzodiazepines
    • alprazolam
    • Baclofen (indicated for muscle spasms, but Euphoria is listed as a common side-effect in the BNF 75, and it can also have anxiolytic effects.)
    • Chlordiazepoxide
    • Clobazam 
    • clonazepam
    • clorazepate
    • diazepam
    • Divaplon
    • Eszopiclone (Lunesta)
    • Fasiplon 
    • gabapentin
    • gabapentin enacarbil
    • gabapentin prodrug
    • Lorazepam
    • midazolam
    • mirogabalin
    • Necopidem
    • Nordazepam
    • Nitrous Oxide
      • (In behavioural tests of anxiety, a low dose of N2O is an effective anxiolytic, and this anti-anxiety effect is associated with enhanced activity of GABAa receptors, as it is partially reversed by benzodiazepine receptor antagonists. )
    • oxazepam
    • Pagoclone
    • Panadiplon 
    • Pazinaclone 
    • phenibut
    • piracetam
    • pregabalin
    • Saripidem
    • Suproclone
    • Suriclone (Suril)
    • Taniplon 
    • Tofisopam (does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing or amnestic properties.)
    • Zaleplon
    • ZK-93423
    • Zolpidem
    • Zopiclone
  • Gabaergics (in development/research)
    • CGS-20625 
    • CGS-9896
    • CL-218,872 
    • DS-1  
    • ELB-139 (LS-191,811)
    • GBLD-345 
    • L-838,417 
    • Lorediplon 
    • NS-2664 (LS-193,048) 
    • NS-2710 (LS-193,970) 
    • RWJ-51204 
    • SB-205384 
    • SL651498
    • SX-3228
    • TP-003 
    • TP-13 
    • TPA-023 (MK-0777)  
    • Y-23684
  • Stimulants
    • methylphenidate
    • dextroamphetamine
  • Antihistamines
    • Atarax (low risk of sexual side effects)
    • Mirtazapine (also a Tetracyclic drug(low risk of sexual side effects)
  • Tricyclic Antidepressants
    • Protriptyline
    • Noxiptiline (brand names Agedal, Elronon, Nogedal)
    • Nortriptyline 
    • Amitriptyline
  • Serotonin Agonists
    • Buspirone (low risk of sexual side effects)
  • Tetracyclic Antidepressants
    • Trazodone
  • SSRIs
    • Citalopram
    • Escitalopram
    • Fluoxetine
    • Fluvoxamine
    • Fluvoxamine controlled release
    • Paroxetine
    • Sertraline
  • Atypical antidepressants
    • Tianeptine
    • mianserin
    • bupropion (low risk of sexual side effects)
    • trazodone
    • nefazodone
    • opipramol
    • agomelatine (low risk of sexual side effects)
  • Serotonin Antagonists 
    • pizotifen
  • Serotonin Modulators
    • Vilazodone (low risk of sexual side effects)
    • Vortioxetine (low risk of sexual side effects)
  • SNRIs
    • Venlafaxine
    • Desvenlafaxine
    • Duloxetine
      • (33.3% of duloxetine patients experienced sexual side effects compared to 43.6% of those receiving escitalopram and 25% of those receiving placebo).
  • Opiates and Opioids
    • Buprenorphine, sold under the brand name Subutex, among others
  • MAOIs
    • Nardil
    • Parnate
    • Selegiline (transdermal patch) (low risk of sexual side effects)
  • Synthetic Cannabinoids
    • Sativex
    • Marinol
    • Epidiolex

Antipsychotics

  • Prochlorperazine (Efficacy established in patients with generalized anxiety disorder -- McEvoy GK, ed. Prochlorperazine. Bethesda, MD: American Society of Health-System Pharmacists; 2005:2342-3)


substituted benzamides

  • Levosulpiride  (used for psychosis, schizophrenia, anxiety, dysthymia)


atypical antipsychotics  

  • Sulpiride ( used in low dosage to treat anxiety and mild depression.)
  • Amisulpride (schizophrenia,  dysthymia)


Others

  • Ketamine (can be used for depression. It induces a trance-like state while providing pain relief, sedation, and memory loss.)
  • Esketamine (In 2019, it was approved for the treatment of depression in adults in the United States. The cost of the nasal spray as of 2019 will be US$4,700 to $6,800 for the first month.)
  • Dextromethorphan (most often used as a cough medicine but can give euphoric effects)


Unknown effect, might be of interest





Herbs and supplements for anxiety:

  • 5HTP (griffonia simplicifolia)
  • Cannabis (high-CBD edibles)
  • CBD oil
  • chamomile capsules
  • GABA capsules (e.g NOW Foods GABA)
  • glycine
  • Holy basil extract
  • hops capsules
  • inositol
  • Lavender capsules
  • lion's mane mushroom
  • Magnesium glycinate
  • Magnesium oil + iodine = zen mode 
  • Magnesium taurate
  • Magnsieum citrate
  • Lemonbalm/melissa capsules
  • niacinamide
  • Omega3
    • ("Emmons recommends a dose of 2,000 to 4,000 mg or more when taken for mood problems")
  • SAMe 200mg (S-Adenosyl-Methionine) 
  • Suntheanine / L-Theanine
  • taurine
    • (take 600mg or more in a single serving)
  • valerian extract capsules
  • vitamin B6
  • Vitamin D3 5000 IU
    • (good for Seasonal Depression, adults should take 5,000 IU per day. )
  • Vitamine C and E works against Oxidative stress



Probiotics for anxiety / depression:

When they give probiotics to mice suffering from autism symptoms, the autism symptoms either go completely away or are strongly ameliorated.

  • Lactobacillus helveticus Rosell-52 ME
  • Bifidobacterium longum Rosell-175 ME
  •  Lactobacillus  acidophilus La14
  • Lactobacillus  Rhamnosus R0011
  • Lactobacillus helveticus R0052
  •  Lactobacillus  casei Lc11
  •   Lactobacillus  paracasei lpc37
  •    Lactobacillus  plantarum lp115
  •   Lactobacillus  salivarius ls33
  •   Bifidobacterium  lactis BI04
  •  Bifidobacterium  breve br03
  •    Bifidobacterium  longum bb536





Misc info
Magnesium and vitamin K2 complement each other, as magnesium helps lower blood pressure, which is an important component of heart disease. So, all in all, anytime you're taking any of the following: magnesium, calcium, vitamin D3, or vitamin K2, you need to take all the others into consideration as well, since these all work synergistically with one another.

Magnesium is required for the biological activation of Vitamin D.
Calcium and magnesium are necessary for muscle function and nervous system health. If you don't have enough, you can have problems with clenching, tension, and other muscle problems.

  • "by using vitamin B3 or niacin or niacinamide, which has effect upon gaba receptors but, after ive started especially With magnesium, manganese and lithium, ive needed much less diazepam when i first use it"

  • Kent Holtorf MD says on twitter: "T3 is the best anti-depressant".

Please inform me if you know about a substance not present in the blog post above.

Drugs/Psychedelics for Anxiety/Depression

Psilocybin & Magic Mushrooms
Writing in the Journal of Psychopharmacology, the Johns Hopkins researchers note that most of the 36 volunteer subjects given psilocybin, under controlled conditions in a Hopkins study published in 2006, continued to say 14 months later that the experience increased their sense of well-being or life satisfaction.
"Most of the volunteers looked back on their experience up to 14 months later and rated it as the most, or one of the five most, personally meaningful and spiritually significant of their lives," says lead investigator Roland Griffiths, Ph.D., a professor in the Johns Hopkins departments of Psychiatry and Behavioral Sciences and Neuroscience.
Griffiths also notes that, "while some of our subjects reported strong fear or anxiety for a portion of their day-long psilocybin sessions, none reported any lingering harmful effects, and we didn't observe any clinical evidence of harm."


<Johns Hopkins Medical Institutions. "Spiritual Effects Of Hallucinogens Persist, Researchers Report." ScienceDaily 2 July 2008. 16 December 2010. http://www.sciencedaily.com­/releases/2008/07/080701083522.htm>

Psilocybin, aka magic mushrooms, actually calms, rather than stimulates, certain brain functions. Psychedelics, and psilocybin in particular, might actually be eliminating what could be called the extra "noise" in the brain. 



LSD-assisted Psychotherapy
Swiss psychiatrist Peter Gasser and his colleagues conducted the double-blind, placebo-controlled study, sponsored by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). They tracked 12 people who were near the end of life as they attended LSD-assisted psychotherapy sessions. In his report, Gasser concluded that the study subjects’ anxiety "went down and stayed down."


MDMA 
The drug MDMA (aka ecstasy, or Molly) promotes release of the "love" hormone oxytocin, which could help treat severe anxieties like PTSD, and social anxiety resulting from autism.

Ayahuasca
The results of the first North American observational study on the safety and long-term effectiveness of ayawaska treatment for addiction and dependence were published in June 2013 in the journal Current Drug Abuse Reviews. All of the participants in the study reported positive and lasting changes, and the study found statistically significant improvements “for scales assessing hopefulness, empowerment, mindfulness, and quality of life meaning and outlook subscales. 


Cannabis

Cannabis strains high in CBD are well suited for reducing anxiety. If you have access to legal medicinal cannabis you have to try it, you have nothing to lose.

Anti-Septics are bad

Dr. Ruebush deplores the current fetish for the hundreds of antibacterial products that convey a false sense of security and may actually foster the development of antibiotic-resistant, disease-causing bacteria. Plain soap and water are all that are needed to become clean, she noted.

“I certainly recommend washing your hands after using the bathroom, before eating, after changing a diaper, before and after handling food,” and whenever they’re visibly soiled, she wrote. When no running water is available and cleaning hands is essential, she suggests an alcohol-based hand sanitizer.


Dr. Weinstock goes even further. “Children should be allowed to go barefoot in the dirt, play in the dirt, and not have to wash their hands when they come in to eat,” he said. He and Dr. Elliott pointed out that children who grow up on farms and are frequently exposed to worms and other organisms from farm animals are much less likely to develop allergies and autoimmune diseases. Also helpful, he said, is to “let kids have two dogs and a cat,” which will expose them to intestinal worms that can promote a healthy immune system.

("Babies Know: A Little Dirt Is Good for You" -- Jane E. Brody, NY Times <http://www.nytimes.com/2009/01/27/health/27brod.html?em>. 26 January 2009)

Philosophical, inspirational, mind-expanding movies

non-exhaustive list

1. Waking Life

Alternative Cancer Treatment


Western Medicine should not be disregarded, for science has given us extraordinary tools of healing. However, in need of medical treatment, why constrict your choices to just western medical science? Seek outside the comfort zone of the medical establishment and you might perchance upon something that works for you. Life, uh, finds a way.


The condition of the organism receiving treatment with either method also plays a big role. Do they have access to clean food? Pure water? Do they believe and feel they can overcome their disease? These are all important factors with any treatment. Even the bedside manners of the doctor affects the patient's recovery and treatment success rate. Positive thinking is also key.

Non-exhaustive list of alternative cancer treatment follows below. It is recommended to thoroughly research each item by yourself and evaluate the claims at your own discretion.


GARLIC
http://www.cancer.gov/cancertopics/factsheet/prevention/garlic-and-cancer-prevention

PH BALANCE
- Learn to maintain your PH and you can prevent and reverse disease such as cancer. A PH between 7.2 and 7.4 is optimal for best health.
- Dr. Robert J. Gillies and his colleagues have already demonstrated the effectiveness of baking soda in alkalinizing the area around tumors in mice. The same researchers found that bicarbonate increases tumor pH and also inhibits spontaneous metastases in mice with breast cancer. [3]
- Lemon is also used to help balance Ph. They are taken together as it is believed that lemon is one of the safest ways to introduce high alkaline substances into the system. These methods of treatment are able to approach carcinogenic cells and destroy them without destroying healthy cells. This is another key factor as chemotherapy destroys all cells which includes the healthy ones.


CANNABIS
Seems extremely divisive unless i'm completely dumb

https://www.startpage.com/do/dsearch?query=cannabis+cures+cancer&cat=web&pl=opensearch&language=english

CANCER IS A FUNGUS?
- Simoncini has a book: “Cancer Is A Fungus”. He claims all tumors are nothing more than colonies of Candida fungus which are highly “acid”. Baking Soda is one of the most alkaline substances known that destroys tumors (Candida fungus) in less than six days and they don’t return.

TURMERIC

BITTER MELON
Bitter melon juice diluted to just 5% in water showed remarkable potency in severely damaging all four pancreatic cancer cell lines researchers tested. The bitter melon reduced the viability of two cancer cell lines by 90%, while it knocked off the other two lines by a staggering 98%. And it did so after just 72 hours of treatment!

APRICOT KERNELS
Apricot kernels are, like most nuts and seeds, very nutritious. Among the nutrients they contain is one called amygdalin, which is also known as vitamin B17. This attacks cancer cells, and thus can help prevent cancer from breaking out in our bodies.


GRAPE SEEDS
A study published in the journal Carcinogenesis shows that grape seed extract (GSE) kills squamous cell carcinoma cells, while leaving healthy cells unharmed.

Shiitake mushrooms

Shiitake contain lentinan which not only strengthens the immune system, but, according to the American Cancer Society, is believed to slow tumor growth. The fungus, native to Asia, is also a good source of iron and antioxidants, which help reduce the damage from free radicals.

Reishi

has shown to contribute to the healing of tumors, while lowering blood sugar and cholesterol levels.

Lactarius salmonicolor
Commonly known as “Turkey Tail”, the mushroom has traditionally been used in Asian herbal remedies. According to the American Cancer Society, two extracts from the mushroom—polysaccharide K (PSK) and polysaccharide-peptide (PSP)—are under evaluation for cancer treatments.

Milk Thistle
An herb that is often processed into capsule form, milk thistle is thought to help delay the growth of cancerous tumors, thanks to its richness in the antioxidant silymarin, according to National Cancer Institute.

Anti-CD47 cancer therapy clinical trials

http://stemcell.stanford.edu/CD47/


POLIO kills cancer?
injecting polio into a tumor may kill the tumor

HIV/AIDS 
kills cancer?
injecting a modified HIV/AIDS virus may kill lymphoma and leukemia

Tuesday, December 20, 2016

Alan Watts on Anxiety (audio)

​These chapters from "Out of your mind" audio lecture series ​by Alan Watts touch on anxiety and social anxiety:

1-07 An Independent System

2-02 Being Aware Of Awareness
2-03 Captivated By The Drama
2-04 The Game Of Hide And Seek
2-06 How Do We Define Ourselves
3-03 A Spontaneous Life
3-04 Seeing Beyond Our Separateness
4-06 What Game Would You Like To Play
5-07 Of Pain And Suffering
5-08 Must Life Go On And On
5-09 A Natural Satori
6-04 The Illusion Of The Ego
6-05 The Meaningless Life
7-05 The Origins Of Zen
10-05 The Limits Of Self-Awareness
11-04 The Cause Of Suffering
12-08 Consider Death Now

Wednesday, May 13, 2015

The Fallacy of the 50% Concordance Rate for Schizophrenia in Identical Twins

Human Nature Review  2003 Volume 3: 406-415 ( 20 September )
URL of this document http://human-nature.com/nibbs/03/joseph.html

by Jonathan Leo


A Review of The Gene Illusion: Genetic Research in Psychiatry and Psychology Under the Microscope by Jay Joseph. 2003, PCCS Books, Ross-on-Wye.

The common practice of treating psychiatric conditions with medications is justified by the belief that mental illnesses are the result of underlying biological deficits. Genetic research is one avenue of research that is frequently cited as proof in support of this belief; and, in turn, one of the most commonly cited pieces of genetic evidence is the concordance rate for identical twins diagnosed with schizophrenia. When discussing schizophrenia twin studies psychiatrists often report a 45%-50% concordance rate for identical twins, compared to only a 15% concordance rate for fraternal twins. These numbers which are often cited in psychiatry textbooks, peer reviewed papers, magazine articles, speeches and even newspaper articles are generally considered the most important piece of evidence supporting the biological theory of schizophrenia-and even as evidence that mental illnesses in general are biologically based. Concerning the genetic theory of schizophrenia, the most recent edition of the neuroscience textbook Fundamental Neuroscience by Squire et al. (2003) states, “The most compelling evidence is the 50% concordance rate for monozygotic twins relative to the 15% concordance for dizygotic twins” (Rapp and Bachevalier, 2003, p. 1193). A new book The Gene Illusion, by Jay Joseph shatters the validity of this statement and leaves the most commonly mentioned statistic in psychiatry in tatters. Joseph’s book is an analysis of psychiatric genetic research and covers topics such as the heritability concept, the genetics of IQ, the genetics of criminality, the schizophrenia adoption studies-but his most devastating criticism is of the schizophrenia twin studies (Joseph, 2003).

It is hard to find any defense of biological psychiatry that does not mention the schizophrenia twin research. As just one example, Steven Hyman, the former-chairman of NIMH, appeared before President George Bush’s Commission on Bioethics for the purpose of defending the meteoric rise in the use of Ritalin and other psychotropic drugs in young children. In his opening monologue he did not cite a study documenting the biological basis of Attention Deficit Hyperactivity Disorder (ADHD); he did not cite a study showing the benefits of Ritalin; instead he cited the “50% schizophrenia twin concordance rate” (see http://www.bioethics.org). His comments, which are not uncommon, are simply an echo of a commonly held belief in psychiatry that if schizophrenia is “genetic” then other psychiatric conditions such as ADHD must also be “genetic.” But in another sense when a psychiatrist defends the biological basis of mental illness and starts the discussion by citing genetic evidence, and not biological evidence such as pathological markers or blood tests, this is a tacit acknowledgement that in fact there is no biological evidence. If there was good biological evidence then why not mention it?

Over the past fifty years the history of psychiatry has been nothing more than the absolute triumph of “nature” over “nurture” -at least in the way the medical community looks at human distress. In the world of biological psychiatry “genes” have won the gold medal and completely pushed “the environment” right off the stage, and no historical analysis of this victory would be complete without a discussion of the schizophrenia twin studies. For instance, if the genetic theory of anorexia never pans out this would have no bearing on the way psychiatrists approach other mental illnesses, but if the most compelling evidence that mental illnesses are genetic is flawed-and that the major cornerstone of the profession is false-then the psychiatry profession has a problem.

Twin studies are important to psychiatric genetic researchers because scientists can compare two different types of twins. Identical twins have the same genotype, while fraternal twins share on average only 50% of the same genes. If the development of a certain disease is due to heredity, then genetic researchers would expect more of the identical twins to share the disease as compared to the same-sex fraternal twins. If the identical twin concordance rate for schizophrenia is 50% and the non-identical twin concordance rate is only 15% then schizophrenia must be genetic-so the thinking goes. If the identical twin concordance rate for schizophrenia is not 50% then what is it? The answer depends on how in-depth you investigate these studies.


How about 40%?

“The 50% concordance rate” comes from pooling numerous schizophrenia twin studies. Joseph presents a table showing all fifteen schizophrenia twin studies conducted from 1928 to 1998 with a range of pairwise identical twin concordance rates from a low of 11% to a high of 69%. Joseph pools the data, does his own calculation and reports that the pooled concordance rate reported with the pairwise method is 40.1%. Thus right at the start the 50% concordance rate is called into question. But why the discrepancy between Joseph’s 40% and the more commonly reported 50%? One reason is due to differences in the way results are reported.

There are two ways that schizophrenia twin researchers report their results. One is the pairwise method, the other is the proband method. Most readers who are not intimately familiar with these studies probably interpret concordance rate findings as the percentage of twin pairs who are both diagnosed with schizophrenia within a sample in which one twin of each pair is known to be schizophrenic. For instance if schizophrenia is diagnosed in both members of 50 twin pairs out of a total sample of 100 then most people would think that the concordance rate is 50%, but it is not that simple. Schizophrenia researchers refer to this type of reporting as the pairwise concordance, yet some prominent researchers prefer to use the proband method of reporting. In the proband method, the proband is the member of a twin pair who was used initially to qualify the pair for inclusion in the sample. It is possible for both members of a twin pair to be probands, in which case that pair would appear twice in the sample. The proband method will always produce higher numbers. As an example, if there is a sample of 3 pairs of twins and in 1 of those pairs both members are diagnosed with schizophrenia then according to the pairwise method the concordance rate would be 1/3 or 33%, but according to the proband-wise method the rate would be 2/4 or 50%.

Of course, certainly some people would say that 40% is still significant, but, Joseph does not stop here; in fact he is just getting started.


How about 20%?

Joseph’s table also highlights another problem with the way the schizophrenia twin research is commonly discussed. From looking at his table it is clear that the more recent studies, which are generally considered more methodologically sound, have lower concordance rates then the older studies. One of the earliest studies was published in 1946 by Franz Kallmann who reported a 69% concordance rate for identical twins. He increased this to 86% after factoring in an age-correction (Kallmann, 1946). Kallmann’s pairwise concordance rate is at odds with many of the more recent studies. Given the fact that Kallmann’s numbers are not in line with the newer studies and that his diagnoses were not blind there seems to be ample reason for not including Kallmann’s data in the pooled calculations. For some people, the fact that Kallmann also believed in compulsory sterilization for people diagnosed with schizophrenia-and their relatives-creates a bit of a problem.

Kallmann’s study was one of the largest twin studies so his study also has a significant effect on the final pooled numbers. But if one pools the nine most recent studies, as Joseph does, starting with Tienari’s 1963 study then the concordance rates are 22.4% for monozygotic twins and 4.6% for fraternal twins.

In the past two decades there have been three schizophrenia studies that found low concordance rates for monozygotic twins; but rather than change the way psychiatrists think about the genetics of mental illness, as Joseph shows, the psychiatry profession would not let the results of these three studies stand for very long.[1]


Tienari, 1936; 1968; 1971;1975

In 1963 Tienari published a twin study which according to Joseph “took the schizophrenia twin-studying world by storm.” Tienari reported that none of the sixteen identical twin pairs in his study were concordant for schizophrenia and that only one fraternal pair out of 21 was concordant. The difference between Kallman’s 85% and Tienari’s 0% identical twin concordance rates could not have been more dramatic, yet only seventeen years separated the two studies. Tienari updated his study several times and in his final 1975 paper Tienari reported an identical twin pairwise figure of 3/20 (15%) and a non-identical twin concordance rate of 3/42 (7.1%).

Gottesman and Shields were the first psychiatric genetic researchers to tackle these numbers and in 1982 wrote that the Tienari’s low concordance rate could be due to the small sample size and the lack of an age-correction factor (Gottesman and Shields, 1982). Some schizophrenia researchers have applied an age-correction factor to their samples to take into account the fact that the subjects might not have passed thru the period in their lives when people are most likely to develop schizophrenia. However, it is unclear why Gottesman thinks that Tienari should have applied an age-correction factor when Tienari’s twins were all over 40 years old and had passed the risk period for schizophrenia. Joseph (and Boyle before him) points out that four other twin studies also had a small sample size and that even Gottesman and Shields own study only had 24 twins. Regardless of these arguments, in his book Schizophrenia Genesis, Gottesman states that Tienari reported a final pairwise concordance rate of 36% for identical twins (Gottesman, 1991, p. 111) when it was actually 15% (3/20) (Tienari, 1975, p. 33).

Tienari’s study also illustrates the problem with reporting findings via the proband method. By 1987 the psychiatric geneticist Kenneth Kendler had converted Tienari’s 3/20 (15%) identical twin pairwise concordance rate into the proband method and reported that Tienari’s concordance rate was 7/21 or 33% (Kendler, 1987). Anyone other than an expert in this field would most likely think that 7 out of 21 pairs were concordant when actually only 3 out 20 pairs or 15% were concordant. [2]


The NAS-NRC Study (Hoffer and Pollin, 1970)

In 1970 Hoffer and Pollin analyzed a large sample of twins from the NAS-NRC veterans sample and reported a pairwise concordance rate for identical twins as 13.8% and for fraternal as 4.1%.

Only two years later Allen and colleagues reanalyzed the study which now included additional twin pairs that had been identified in the meantime. The new identical twin concordance rate was reported as 27% and fraternal 4.8% (Allen, Cohen, and Pollin, 1972). However these figures were obtained by widening the diagnostic criteria. In 1982 Gottesman and Shields converted the 27% identical twin pairwise concordance to a probandwise rate of 43%. Somehow mainstream psychiatry researchers had transformed an initially reported rate of 13.8% to 43%. [3].


Koskenvuo, Langinvainio, Kaprio, Lonnqvist, and Tienari, 1984

This study had one of the largest samples of twins, yet is almost never acknowledged by schizophrenia twin researchers in their reviews; interestingly, they have not explained why it has been left out of their reviews. In the Koskenvuo study the concordance rate was 11% for identical twins and 1.8% for fraternals.

So even before getting into any real analysis or much controversy, for that matter, it is clear that there is very little justification for saying that there is 50% concordance rate for monozygotic twins, and little justification for textbooks authors and review authors to pool the older studies with the more carefully designed newer studies. At the very least, these authors should be pointing out the discrepancies between the more recent studies and the older studies. Going one step further, textbook authors should probably point out that the newer studies have actually revealed the fallacy of the “50% concordance rate.”

If you think I am being extreme here ask yourself this question: If the chronological order of these studies were reversed and the older biased studies had, say, a 20% concordance rate and the newer less biased studies had a 86% concordance rate would psychiatry and genetic researchers still be pooling the data or would they be citing a concordance rate closer to 86%?

Like much of the psychiatry literature, the more one examines the initial claims of psychiatry researchers the more the validity of those claims is called into question. In the case of schizophrenia twin research it does not take much more than scratching below the surface to see that textbooks would be more correct to write about a 20% concordance rate for schizophrenia in identical twins - and that is simply based on a more accurate reporting of the original authors’ research.

Certainly the proponents of the genetic theory of schizophrenia will take issue with some of Joseph’s analysis-such as using the pairwise rather than probandwise reporting method, or the validity of Kallmann’s data. But as Joseph points out, staring these critics directly in the face is a very telling statistic: In three modern schizophrenia twin studies 84% of the identical twins were judged discordant for schizophrenia.

Even an acknowledgement by the main stream psychiatry profession that the schizophrenia concordance rate was closer to 20% would necessitate a rewording of many of their core tenets. There are twin studies of diseases with well-known biological factors that some psychiatrists have equated with schizophrenia, but the language used to discuss these diseases is very different from the language used to discuss psychological trauma. Take the conclusions in a paper that used the classical twin method to investigate the role of genetics in a disease with a known biological marker. Based on a concordance rate of 30.8% for identical twins and 4.7% for non-identical twins the authors concluded that there was a genetic component to the disease, but they also had this to say about the environment: 

-The data from this twin study also have important implications for the nature of environmental or non-heritable effects on the development.

-This unambiguously demonstrates the powerful effect of nonheritable factors.

-Taken in sum, these observations are entirely consistent with a broader concept of the role of the environment (Sadovnick, Armstrong, Rice et al., 1993, p. 285) 

 The disease these researchers are talking about is multiple sclerosis (MS) and even though they attribute a portion of the etiology of MS to genetics, they go out of their way to point out that the environment is just as, if not more, important than genetics. [4] A handout for the general public, from the Multiple Sclerosis Genetics Research Group tells people that “in some combinations these normal genes appear to predispose some individuals to develop MS after exposure to an undefined environmental factor or factors” (italics added). It’s hard to imagine a patient handout on psychological distress saying “normal genes appear to predispose some individuals to develop depression after exposure to an undefined environmental factor” or a neurology textbook saying that the strongest evidence for the biological basis of MS comes from twin studies.

However if one digs a little deeper, then even the idea that there is a 20% concordance rate is highly suspect. For Joseph, even a 20% concordance rate means little because the twin methodology is based on a fundamentally flawed assumption. [5] But before reading further ask yourself this common sense question: Do you think that families, teachers, friends, and society in general treat identical twins more alike than non-identical twins?


Is the Twin Method Valid?

The validity of the twin method is based on answering “No” to this question. The classical twin method assumes that identical twins do not have more similar environments than fraternal twins. This equal environment assumption, or EEA, is critical for the twin method because if identical twins are treated more alike than fraternal twins then any difference in the concordance rates between the two types of twins could be attributed to their environment. Psychiatric geneticists will have a much more difficult time with this part of the book because Joseph is not just saying that this flawed assumption might cause a slight overemphasis on the side of genetics, rather he is saying that because the EEA is false it is impossible to draw any meaningful conclusions from twin studies. In his words, “ the entire theoretical basis for twin studies that look at genetic components of human behavior and psychiatric conditions stands or falls on the veracity of this assumption” (Joseph, 1998, p. 329).

One way of testing the equal environment assumption is to compare fraternal twins to other siblings because in terms of their genetic makeup fraternal twins are no more alike than non-twin siblings so any difference in the rate of schizophrenia between fraternal twins and siblings must be due to something other then genes. Six of the schizophrenia twin studies also compared the concordance rates between fraternal twins and non-twin siblings and five of these studies found that fraternal twins had a higher concordance rate compared to non-twin siblings, and in two of these studies the differences were significant (Leo and Joseph, 2002). The only study that found a similar rate was by Kallmann. There are several other ways of evaluating the EEA in schizophrenia, and Joseph devotes a considerable amount of text to this discussion. As just one example, Joseph pools the data from those twin studies that report both the same-sex fraternal and opposite-sex fraternal twin concordance rates. The same-sex fraternal concordance rate is 11.3% and the opposite-sex fraternal rate is 4.7%. This difference is hard to explain based on genetics, but most twin researchers simply ignore the data. [6] Even if you do not agree completely with Joseph’s view that the twin studies are invalidated by the flawed EEA, it is clear from his book that the majority of the secondary sources, like the textbook cited at the beginning of this review, that discuss the schizophrenia twin studies are seriously flawed.


Susceptibility Genes

An interesting twist to this discussion concerns the recent paper in Science about the discovery that individuals with at least one copy of the short allele of the 5-HTT promoter polymorphism were more susceptible to depression if they were also exposed to a series of traumatic events (Caspi, Sugden, Moffitt et al., 2003). Some researchers have said that this study will aid in identifying people prone to depression even though in the group of clinically depressed patients exposed to four traumatic events 86% of them carried at least one copy of the short allele, or susceptibility gene, while in the group exposed to four traumatic events who did not become depressed, 72% were also carriers of the short allele. It is unclear how this information would aid in identifying who is susceptible to depression or, even more controversial, what type of treatment would be provided. Imagine the interaction between a doctor and a clinically depressed patient who had experienced four traumatic events; it would seem that the most important element in this interaction would be the traumatic events, and not whether the person had the short allele. The person’s genetic makeup is entirely unnecessary for any explanation of the depression and the “genetics” in no way implies that drugs are needed. But most importantly, and not mentioned in many of the newspaper accounts of this study, is that 68% of the population carries at least one copy of this allele. [7] These investigators have not discovered anything unique about people diagnosed with depression, rather they have discovered something very general about human nature-more then 2/3rds of us carry an allele that makes us susceptible to depression after suffering a series of traumatic events. In addition, even people without the short form became depressed; serotonin processing has been implicated in numerous DSM-IV conditions; and this allele is most likely involved in many other traits-some of which might be considered beneficial.

If the majority of us are susceptible to depression after a series of traumatic events this certainly calls into question the “line” that psychiatrists have drawn between normal and abnormal. Is depression following traumatic events part of our humanity? Is it possible that someone who is “normal” can be labeled as “abnormal?” Is the drug treating a “disease” or covering up a normal reaction to stress? The study seems to raise more questions about the wisdom of the widespread use of psychotropic drugs than it answers. The authors of the study stated: “Until this study’s findings are replicated, speculation about clinical implications is premature” (p. 389). Yet have they really thought through this comment? If this study is replicated tomorrow what clinical plan are these scientists even remotely entertaining?

Perhaps one of the more confusing statements from psychiatric genetic researchers appears in a recent issue of Science. In a discussion of “ADHD genes” Steven Faraone stated: “My hope is that once we’ve discovered those genes, we’ll be able to do a prospective study of kids at high versus low genetic risk. That’s when you’ll see environmental factors at work.” But certainly one can still see environmental factors at work in children without knowing their genotype; Maria Montessori saw the importance of environmental factors 60 years ago. Yet, even more confusing is Faraone’s next comment. According to the reporter, “Eventually, he (Faraone) adds, environmental changes could play an important role in treating some ADHD patients” (Brown, 2003, p. 160). Eventually? What are we waiting for? Why not implement the changes right now? Changing the environment is exactly what many people opposed to Ritalin have been saying for years. Faraone seems to be falling right in line with Thom Hartmann who believes that children with ADHD are not dysfunctional but have different genes-hunter gatherer genes-and that what is needed is a different environment (Hartmann, 1996). Apparently Faraone cannot give credence to a role for the environment in the etiology of ADHD without knowing the genotype. He should probably elaborate on what environmental changes he has in mind for a child who does not want to sit still in school, why these changes could not implemented right now, and how knowing the genotype will aid in developing a plan. Faraone has certainly put a very unique twist on the whole discussion by saying that once we know genotypes we can alter the environment, but in one sense his discussion can’t really be taken too seriously; because allowing for a dose of reality, anyone remotely familiar with the topic of genetic susceptibility is all too aware that right around the corner is the real pitch-the medication tie-in. An earlier statement by Faraone is much more representative of how genetic research is more often used: “Many parents are reluctant for their children to take psychotropic medication and others find it difficult to maintain the prescribed regimes. These problems are mitigated by discussing the genetic etiology of ADHD…” (Faraone, 1996, p. 598).

Quite simply, main-stream psychiatry is in a position where, for political and economic reasons, they could never acknowledge that the conditions they treat have more to do with environmental causes then genetic predispositions. Take ADHD for example, the problem for the Ritalin proponents is that they could never publicly admit that treating so many children with psychotropic drugs has anything at all to do with the environment. If they admitted that something like smaller classrooms could lead to a decrease in psychotropic drug use the façade of treating a medical condition would be revealed. All of sudden Ritalin would go from being advertised as something to treat a medical condition, to a drug that is “quick, easy and cheap”-at least compared to changing the environment. In the world of American pop culture, the current view of mental illness is that someone is walking down the street, everything is going fine, life is good and then out of the blue, there is a chemical shortage. At the route of every twisted thought is a twisted molecule and at the route of every twisted molecule is a twisted gene so the theory goes. This portrayal of mental illness has certainly served its purpose as a marketing tool, yet it is becoming increasingly harder to justify this view based on a realistic appraisal of the science.

Besides having profound implications for the science of biological psychiatry, a debunking of the “50% concordance rate” also has implications for the clinical side of biological psychiatry. Patients diagnosed with a mental illness are often told that their condition is due to a problematic gene which is causing a biochemical imbalance. Because there are no neuropathological markers for psychiatric disorders a psychiatric diagnosis is based on a careful patient history that includes questions about mental illnesses in other family members. The idea being that when a psychiatrist is examining a patient and deciding what psychiatric diagnosis to make, or even whether to make a psychiatric diagnosis at all, a family history of mental illness can sway the decision one way or another. Thus, the diagnosis of an individual patient is based, in part, on a previous diagnosis in another family member. Some psychiatry researchers have taken this to the extreme and claim that they can identify people who are “at-risk” of developing schizophrenia. Not surprisingly, one of the risk factors these researchers use to identify candidates for pre-psychotic treatment is a family history of schizophrenia. But as Joseph’s book documents, making a diagnosis of schizophrenia, or predicting who will get schizophrenia, based on a family history has little scientific rationale.


Conclusions

I have only touched on one aspect of Joseph’s book, but his book covers much more than the identical twin schizophrenia concordance rate. In fact, the section on the schizophrenia twin data is only 20 pages out of a 334-page book. For those psychiatrists who point out that the famous schizophrenia adoption studies have confirmed the genetic theory of schizophrenia Joseph has a whole chapter. As just a teaser, how many psychiatrists are aware that the most often cited schizophrenia adoption study rests its case on the basis of counting spectrum disorders among index and control paternal half-siblings?

Many of the recent popular books on nature vs. nurture have taken at face value what behavioral geneticists have previously written in review articles and textbooks. Take Steven Pinker’s recent book The Blank Slate about the importance of genetics in the molding of human traits (Pinker, 2002). For Pinker, the twin studies are one of the most important supporting pieces of evidence for his argument, yet regarding the EEA-an assumption on which the twin method succeeds or fails-he devotes about two sentences plus a citation to a twin expert. Like Pinker, there are many authors who attempt to take the existing body of knowledge on nature and nurture and work out where on the continuum between the two extremes the truth falls. But these authors bring to the table a set of assumptions like “the 50% concordance rate” that they have primarily taken from secondhand sources. Joseph’s book is not about trying to work out a happy medium on the nature-nurture continuum by analyzing secondary sources. Instead he has gone right to the original studies, analyzed them, pointed out the problems with these studies, and in the process has revealed that the “grand synthesizers” of the nature versus nurture debate have based their work on a set of questionable assumptions.

It will be interesting to see how, or even if, the psychiatry profession responds to Joseph’s book, because for the most part the profession has ignored him. As of this point no American publisher has picked up his book; and many of his previously published papers which formed the basis for the book did not come from mainstream psychiatry journals, but instead came from less well known journals. The profession that has written and published thousands of pages about the schizophrenia twin and adoption studies but few papers pointing out the simple fact that the newer more methodologically sound schizophrenia twin studies have found only a 22.4% identical twin concordance rate. Or that the most-often cited schizophrenia adoption study is based on the diagnosis of spectrum disorders in half-siblings? Of course people will be arguing about the nuances of individual twin studies for years, and you might not agree with all of Joseph’s critique; but after reading his book, the next time you see an announcement in the paper about the discovery of a gene for emotional distress you will be a little more skeptical. The problem for the psychiatry profession is that Joseph’s readers will likely take his debunking of the “50% concordance rate” one step further and question the entire scientific basis for biological psychiatry.

National Public Radio recently aired a piece describing how in the future we can swab our cheeks, send the sample off to a company, and conveniently find out all the genes we carry for various diseases such as schizophrenia. I talked to the author of the piece and pointed out to him that no one has discovered a gene for schizophrenia. He referred me to his source which was a company involved in the enthusiastic race to find a gene, or genes, for schizophrenia. No doubt the search for genes for schizophrenia and other DSM-IV conditions will continue at a frantic pace, and it is certainly this company’s prerogative to spend millions of their dollars in the hunt for these genes. However, if Joseph is correct they would probably be better off trying the slot machines.

Notes

1. Joseph’s discussion builds on Mary Boyle’s discussion in her 1990 book Schizophrenia: A Scientific Delusion (Boyle, 1990).

2. The basis for Kendler reporting 7/21 even with the proband method is unclear.

3. In 1983 Kendler and Robinette created a wider diagnostic category and reanalyzed the original sample and still only found a pairwise identical twin concordance rate for schizophrenia of 18.3% (30/164) (Kendler and Robinette, 1983).

4. This study also found no difference between the non-identical twins and other siblings which is confirmatory evidence for the validity of the EEA regarding multiple sclerosis. This is not the case for the schizophrenia twin studies.

5. There are other scientists that have written that the true concordance rate is closer to 25% (Torrey, 1992).

6. In 1982 Gottesman and Shields claimed that there is no difference between same sex and opposite sex fraternals in recent studies. But by recent studies they were referring to one study-Kringlen’s 1967 investigation (see Joseph 2002, p. 150).

7. 68% of the New Zealanders in this study had at least one copy of the short allele. It is possible that this allele could vary between different groups, or races, of people.

References

Allen, M. G., Cohen, S., and Pollin, W. (1972). Schizophrenia in veteran twins: A diagnostic review. American Journal of Psychiatry, 128:, 939-945.

Boyle, M. (1990). Schizophrenia: A scientific delusion. New York: Routledge.

Brown, K. (2003). New attention to ADHD genes. Science, 301: 160-161.

Caspi, A., Sugden, K., Moffitt, T., Taylor, A., Craig, I. W., Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., and Poulton, R. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science, 301: 386-389.

Faraone, S. (1996). Discussion of "Genetic influence on parent-reported attention-related problems in a Norwegian general population twin sample." Journal of American Academy of Child and Adolescent Psychiatry, 35: 596-598.

Gottesman, I., and Shields, J. (1982). Schizophrenia: The epigenetic puzzle. New York: Cambridge University Press.

Gottesman, I. I. (1991). Schizophrenia genesis: The origins of madness. New York: Freeman.

Hartmann, T. (1996). Beyond ADHD: Hunting for reasons in the past and present. Grass Valley, CA: Underwood Books.

Hoffer, A., and Pollin, W. (1970). Schizophrenia in the NAS-NRC panel of 15,909 veteran twin pairs. Archives of General Psychiatry, 23: 469-477.

Joseph, J. (1998). The equal environment assumption of the classical twin method: A critical analysis. Journal of Mind and Behavior, 19: 325-358.

Joseph, J. (2003). The gene illusion: Genetic Research in psychiatry and psychology under the microscope. Herefordshire: PCCS Books.

Kallmann, F. J. (1946). The genetic theory of schizophrenia: An analysis of 691 schizophrenic twin index families. American Journal of Psychiatry, 103: 309-322.

Kendler, K. (1987). The genetics of schizophrenia: A current perspective. In H. Meltzer (Ed.), Psychopharmacology: The third generation of progress (pp. 705-713). New York: Raven Press.

Kendler, K., and Robinette, C. D. (1983). Schizophrenia in the national academy of sciences-national research council twin registry: A 16 year update. American Journal of Psychiatry, 14:1551-1563.

Koskenvuo, M., Langinvainio, H., Kaprio, J., Lonnqvist, J., and Tienari, P. (1984). Psychiatric hospitalization in twins. Acta Geneticae Medicae et Gemellologiae (Roma), 33: 321-332.

Leo, J. L., and Joseph, J. (2002). Schizophrenia: Medical students are taught it's all in the genes, but are they hearing the whole story. Ethical Human Sciences and Services, 4(1): 17-30.

Pinker, S. (2002). The blank slate: The modern denial of human nature. New York: Viking Penguin.

Rapp, P. R., and Bachevalier, J. (2003). Cognitive development and aging. In L. R. Squire, and F. E. Bloom, and S. K. McConnell, and J. L. Roberts, and N. C. Spitzer, and M. J. Zigmond (Eds.), Fundamental neuroscience (pp. 1167-1199). New York: Academic Press.

Sadovnick, A. D., Armstrong, H., Rice, G. P., Bulman, D., Hashimoto, L., Paty, D. W., et al. (1993). A population-based study of multiple sclerosis in twins: update. Annals of Neurology, 33: 281-285.

Tienari, P. (1963). Psychiatric illness in identical twins. Copenhagen: Munksgaard.

Tienari, P. (1968). Schizophrenia in monozygotic twins. In D. Rosenthal and S. Kety (Eds.), The transmission of schizophrenia (pp. 27-36). New York: Pergamon Press.

Tienari, P. (1971). Schizophrenia and monozygotic twins. Psychiatria Fennica, 1971, 97-104.

Tienari, P. (1975). Schizophrenia in Finnish male twins. In M. H. Lader (Ed.), British Journal of Psychiatry Special Publication, No. 10 (pp. 29-35).

Torrey, E. F. (1992). Are we overestimating the genetic contribution to schizophrenia? Schizophrenia Bulletin, 18: 159-170.